查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1396987

多重诊断市场：按产品类型、应用、最终用户划分：2023-2032 年全球机会分析与产业预测

Multiplexed Diagnostics Market By Product Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 425 Pages | 商品交期: 2-3个工作天内

价格

预计2022年全球多重诊断市场规模将达107亿美元，2032年将达415亿美元，2023年至2032年复合年增长率为14.5%。

多重检测是一种诊断测试同时检测或识别多种生物标记的过程，使其可用于多种不同类型的疾病。例如，心血管疾病患者的药物基因组学研究表明，多态性的存在会影响患者对各种药物的反应。因此，相关生物标记的多重检测不仅可以深入了解心血管疾病的病理，而且可以指南最有效的治疗方法。

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 个人化医疗需求不断成长
      • 慢性病增加
      • 多重诊断产品的技术进步
    • 抑制因素
      • 多重诊断相关的高成本
    • 机会
      • 扩大多重诊断试剂的应用

第四章多重诊断市场：依产品类型

  • 概述
  • 设备/配件
  • 套件/试剂

第五章多重诊断市场：依应用分类

  • 概述
  • 感染疾病
  • 肿瘤学
  • 自体免疫疾病
  • 心臟病
  • 过敏
  • 其他的

第六章多重诊断市场：依最终使用者分类

  • 概述
  • 医院
  • 诊断中心
  • 其他的

第七章多重诊断市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 澳洲
    • 印度
    • 韩国
    • 其他的
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他的

第八章 竞争形势

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争仪表板
  • 竞争热图
  • 2022年主要企业定位

第九章 公司简介

  • Co-Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Agilent Technologies, Inc.
  • BioMerieux SA
  • Illumina Inc.
  • Hologic Inc.
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories Inc
  • Siemens Healthineers AG
  • Diasorin SpA
Product Code: A15440

The global multiplexed diagnostics market was valued at $10.7 billion in 2022, and is projected to reach $41.5 billion by 2032, growing at a CAGR of 14.5% from 2023 to 2032.Multiplexing is the process of simultaneously detecting or identifying multiple biomarkers in a single diagnostic test, which can be valuable for several different types of diseases. For instance, pharmacogenomic studies in patients with cardiovascular disease have indicated that the presence of polymorphisms affects response of a patient to various drugs. The multiplex detection of relevant biomarkers, hence, not only provides insight into the pathophysiology of cardiovascular disease, but also serves as a guide for the most efficient treatment option.

In addition, multiplex tests simultaneously analyze samples for multiple pathogens. Currently, available multiplex tests, including those from the life sciences company Thermo Fisher Scientific, leverage PCR techniques to selectively amplify genes specific to each virus of interest. For SARS-CoV-2, the test might amplify genes that code for the envelope protein (E gene) of the virus or the nucleocapsid protein (N gene). Targets may include virus specific matrix proteins as well as nucleocapsid proteins for Influenza A, B, and Respiratory syncytial virus (RSV), polymerase chain reaction (PCR).

Major factors that drive the growth of the global multiplexed diagnostics market include an increase in need for automated equipment and varied analytical methodologies, increase in incidence of disease outbreaks such as coronavirus and Ebola virus, and surge in technological innovations in assay design, detection methods, and data analysis techniques.

Furthermore, increase in R&D investment in pharmaceutical & biotechnology industries for the development of novel drug therapies and increase in prevalence of chronic diseases such as cancer, cardiovascular diseases, and autoimmune disorders are the major factors that increase the demand for multiplexed diagnostics tests kits and instruments and hence propel the growth of the market.

In addition, the increase in the number of key market players and the strategies they adopt for the development of technologically advanced multiplexed diagnostics products are the major factors that boost the growth of the multiplexed diagnostics market. For instance, in January 2023, Agilent Technologies, Inc. announced a partnership with Akoya Biosciences, Inc. to develop multiplex-immunohistochemistry diagnostic solutions for tissue analysis and to commercialize workflow solutions for multiplex assays in the clinical research market. Integrating Dako Omnis (auto-staining instrument) of Agilent and PhenoImager HT (imaging platform) of Akoya for multiplex chromogenic immunohistochemistry (mIHC) and immunofluorescent (mIF) assays create a singular end-to-end commercial workflow, including reagents, staining, imaging, and analysis.

However, the high cost associated with multiplexed diagnostic assay, and lack of skilled professionals to operate diagnostic tools and conduct multiplexed diagnostic assay restrain the growth of the multiplexed diagnostics market. On the contrary, the surge in the demand for novel home health monitoring systems such as increase in demand for xPOCT devices, which ensure the quality and performance requirements of in vitro diagnostics, performed in a short period by non-experts and increased use of personalized medicine are expected to provide additional opportunities for the multiplexed diagnostics market to grow during the forecast period.

The multiplexed diagnostics market is segmented into product type, application, end user, and region. On the basis of product type, the market is bifurcated into instruments & accessories and kits & reagents. On the basis of application, it is segregated into infectious disease, oncology, autoimmune disease, cardiac disease, allergies, and others. On the basis of end user, it is segmented into hospitals, diagnostic centers, and others. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are Co-Diagnostics, Inc. Agilent Technologies, Inc., bioMerieux SA, Illumina Inc., Hologic, Inc. Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., and DiaSorin S.p.A. The key players such as bioMerieux SA, Hologic, Inc. F. Hoffmann-La Roche Ltd., Agilent Technologies Inc, Bio-Rad Laboratories and DiaSorin S.p.A have adopted product launch, product approval, acquisition, and partnership as major developmental strategies to improve the product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the multiplexed diagnostics market analysis from 2022 to 2032 to identify the prevailing multiplexed diagnostics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the multiplexed diagnostics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global multiplexed diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • New Product Development/ Product Matrix of Key Players
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Average Selling Price Analysis / Price Point Analysis
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Product Type

  • Instruments and Accessories
  • Kits and Reagents

By Application

  • Infectious Disease
  • Oncology
  • Autoimmune Diseases
  • Cardiac Diseases
  • Allergies
  • Others

By End User

  • Hospitals
  • Diagnostic Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Agilent Technologies, Inc.
    • Hologic Inc.
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • BioMerieux SA
    • F. Hoffmann-La Roche Ltd.
    • Diasorin S.p.A.
    • Illumina Inc.
    • Bio-Rad Laboratories Inc
    • Co-Diagnostics, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Growth in demand for personalized medicine
      • 3.4.1.2. Rise in prevalence of chronic disease
      • 3.4.1.3. Technological advancements in multiplexed diagnostics products
    • 3.4.2. Restraints
      • 3.4.2.1. High cost associated with multiplexed diagnostics
    • 3.4.3. Opportunities
      • 3.4.3.1. Expansion of applications of multiplexed diagnostics

CHAPTER 4: MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Instruments and Accessories
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Kits and Reagents
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Infectious Disease
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Oncology
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Autoimmune Diseases
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Cardiac Diseases
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Allergies
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Others
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country

CHAPTER 6: MULTIPLEXED DIAGNOSTICS MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Diagnostic Centers
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: MULTIPLEXED DIAGNOSTICS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Product Type
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Product Type
      • 7.2.5.1.2. Market size and forecast, by Application
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Product Type
      • 7.2.5.2.2. Market size and forecast, by Application
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Product Type
      • 7.2.5.3.2. Market size and forecast, by Application
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Product Type
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Product Type
      • 7.3.5.1.2. Market size and forecast, by Application
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Product Type
      • 7.3.5.2.2. Market size and forecast, by Application
      • 7.3.5.2.3. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Product Type
      • 7.3.5.3.2. Market size and forecast, by Application
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Product Type
      • 7.3.5.4.2. Market size and forecast, by Application
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Product Type
      • 7.3.5.5.2. Market size and forecast, by Application
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Product Type
      • 7.3.5.6.2. Market size and forecast, by Application
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Product Type
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Product Type
      • 7.4.5.1.2. Market size and forecast, by Application
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Product Type
      • 7.4.5.2.2. Market size and forecast, by Application
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Market size and forecast, by Product Type
      • 7.4.5.3.2. Market size and forecast, by Application
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. India
      • 7.4.5.4.1. Market size and forecast, by Product Type
      • 7.4.5.4.2. Market size and forecast, by Application
      • 7.4.5.4.3. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Product Type
      • 7.4.5.5.2. Market size and forecast, by Application
      • 7.4.5.5.3. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Product Type
      • 7.4.5.6.2. Market size and forecast, by Application
      • 7.4.5.6.3. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Product Type
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Product Type
      • 7.5.5.1.2. Market size and forecast, by Application
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Product Type
      • 7.5.5.2.2. Market size and forecast, by Application
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Product Type
      • 7.5.5.3.2. Market size and forecast, by Application
      • 7.5.5.3.3. Market size and forecast, by End User
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Product Type
      • 7.5.5.4.2. Market size and forecast, by Application
      • 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Co-Diagnostics, Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. F. Hoffmann-La Roche Ltd.
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Agilent Technologies, Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. BioMerieux SA
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Illumina Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Hologic Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Thermo Fisher Scientific Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Bio-Rad Laboratories Inc
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Siemens Healthineers AG
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Diasorin S.p.A.
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 02. MULTIPLEXED DIAGNOSTICS MARKET FOR INSTRUMENTS AND ACCESSORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. MULTIPLEXED DIAGNOSTICS MARKET FOR KITS AND REAGENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 05. MULTIPLEXED DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. MULTIPLEXED DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. MULTIPLEXED DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. MULTIPLEXED DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. MULTIPLEXED DIAGNOSTICS MARKET FOR ALLERGIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. MULTIPLEXED DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 12. MULTIPLEXED DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. MULTIPLEXED DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. MULTIPLEXED DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. MULTIPLEXED DIAGNOSTICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA MULTIPLEXED DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 20. U.S. MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 21. U.S. MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. U.S. MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. CANADA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 24. CANADA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. CANADA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. UK MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 40. UK MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. UK MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. ITALY MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 43. ITALY MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. ITALY MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. CHINA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 59. CHINA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. CHINA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. INDIA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 65. INDIA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. INDIA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 76. LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 79. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 81. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 82. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 89. CO-DIAGNOSTICS, INC.: KEY EXECUTIVES
  • TABLE 90. CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT
  • TABLE 91. CO-DIAGNOSTICS, INC.: PRODUCT SEGMENTS
  • TABLE 92. CO-DIAGNOSTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 93. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 94. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 95. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 96. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 97. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
  • TABLE 98. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 99. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 100. AGILENT TECHNOLOGIES, INC.: PRODUCT SEGMENTS
  • TABLE 101. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 102. AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
  • TABLE 103. BIOMERIEUX SA: KEY EXECUTIVES
  • TABLE 104. BIOMERIEUX SA: COMPANY SNAPSHOT
  • TABLE 105. BIOMERIEUX SA: PRODUCT SEGMENTS
  • TABLE 106. BIOMERIEUX SA: PRODUCT PORTFOLIO
  • TABLE 107. BIOMERIEUX SA: KEY STRATERGIES
  • TABLE 108. ILLUMINA INC.: KEY EXECUTIVES
  • TABLE 109. ILLUMINA INC.: COMPANY SNAPSHOT
  • TABLE 110. ILLUMINA INC.: PRODUCT SEGMENTS
  • TABLE 111. ILLUMINA INC.: PRODUCT PORTFOLIO
  • TABLE 112. HOLOGIC INC.: KEY EXECUTIVES
  • TABLE 113. HOLOGIC INC.: COMPANY SNAPSHOT
  • TABLE 114. HOLOGIC INC.: PRODUCT SEGMENTS
  • TABLE 115. HOLOGIC INC.: PRODUCT PORTFOLIO
  • TABLE 116. HOLOGIC INC.: KEY STRATERGIES
  • TABLE 117. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 118. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 119. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
  • TABLE 120. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 121. BIO-RAD LABORATORIES INC: KEY EXECUTIVES
  • TABLE 122. BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT
  • TABLE 123. BIO-RAD LABORATORIES INC: PRODUCT SEGMENTS
  • TABLE 124. BIO-RAD LABORATORIES INC: PRODUCT PORTFOLIO
  • TABLE 125. BIO-RAD LABORATORIES INC: KEY STRATERGIES
  • TABLE 126. SIEMENS HEALTHINEERS AG: KEY EXECUTIVES
  • TABLE 127. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
  • TABLE 128. SIEMENS HEALTHINEERS AG: PRODUCT SEGMENTS
  • TABLE 129. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
  • TABLE 130. DIASORIN S.P.A.: KEY EXECUTIVES
  • TABLE 131. DIASORIN S.P.A.: COMPANY SNAPSHOT
  • TABLE 132. DIASORIN S.P.A.: PRODUCT SEGMENTS
  • TABLE 133. DIASORIN S.P.A.: PRODUCT PORTFOLIO
  • TABLE 134. DIASORIN S.P.A.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF MULTIPLEXED DIAGNOSTICS MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN MULTIPLEXED DIAGNOSTICS MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN MULTIPLEXED DIAGNOSTICS MARKET (2023-2032)
  • FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR INSTRUMENTS AND ACCESSORIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR KITS AND REAGENTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR ALLERGIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. MULTIPLEXED DIAGNOSTICS MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 26. U.S. MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. CANADA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. MEXICO MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. GERMANY MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. FRANCE MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. UK MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. ITALY MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. SPAIN MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. REST OF EUROPE MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. JAPAN MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. CHINA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. INDIA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. REST OF ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. REST OF LAMEA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. TOP WINNING STRATEGIES, BY YEAR (2021-2023)
  • FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2023)
  • FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY (2021-2023)
  • FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 49. COMPETITIVE DASHBOARD
  • FIGURE 50. COMPETITIVE HEATMAP: MULTIPLEXED DIAGNOSTICS MARKET
  • FIGURE 51. TOP PLAYER POSITIONING, 2022
  • FIGURE 52. CO-DIAGNOSTICS, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 53. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. AGILENT TECHNOLOGIES, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. AGILENT TECHNOLOGIES, INC.: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 57. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. BIOMERIEUX SA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. BIOMERIEUX SA: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 61. BIOMERIEUX SA: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 62. ILLUMINA INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. ILLUMINA INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 64. ILLUMINA INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. HOLOGIC INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. HOLOGIC INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. HOLOGIC INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 68. THERMO FISHER SCIENTIFIC, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 69. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 70. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 71. BIO-RAD LABORATORIES INC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 72. BIO-RAD LABORATORIES INC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 73. BIO-RAD LABORATORIES INC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 74. SIEMENS HEALTHINEERS AG: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 75. SIEMENS HEALTHINEERS AG: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 76. SIEMENS HEALTHINEERS AG: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 77. DIASORIN S.P.A.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 78. DIASORIN S.P.A.: REVENUE SHARE BY REGION, 2021 (%)